Nektar Therapeutics Aktie
WKN: 165417 / ISIN: US6402681083
|
18.09.2025 23:34:03
|
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today
Clinical-stage biotech Nektar Therapeutics (NASDAQ: NKTR) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances, investors flocked to the stock, and it closed the trading session a bit more than 15% higher. With that rise, it crushed the 0.5% advance of the bellwether S&P 500 index. That morning, Nektar published new data from a phase 2b study of rezpegaldesleukin, which targets moderate to severe atopic dermatitis, a skin disorder. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!